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Abstract
Background: Tuberculosis patients receiving anti-tuberculosis treatment may experience serious adverse drug reactions,
such as hepatotoxicity. Genetic risk factors, such as polymorphisms of the NAT2, CYP2E1 and GSTM1 genes, may increase
the risk of experiencing such toxicity events. Many pharmacogenetic studies have investigated the association between
genetic variants and anti-tuberculosis drug-related toxicity events, and several meta-analyses have synthesised data from
these studies, although conclusions from these meta-analyses are conflicting. Many meta-analyses also have serious
methodological limitations, such as applying restrictive inclusion criteria, or not assessing the quality of included studies.
Most also only consider hepatotoxicity outcomes and specific genetic variants. The purpose of this systematic review and
meta-analysis is to give a comprehensive evaluation of the evidence base for associations between any genetic variant
and anti-tuberculosis drug-related toxicity.
Methods:We will search for studies in MEDLINE, EMBASE, BIOSIS and Web of Science. We will also hand search
reference lists from relevant studies and contact experts in the field. We will include cohort studies, case–control
studies and randomised controlled trials that recruited patients with tuberculosis who were either already established
on anti-tuberculosis treatment or were commencing treatment and who were genotyped to investigate the effect of
genetic variants on any anti-tuberculosis drug-related toxicity outcome. One author will screen abstracts to identify
potentially relevant studies and will then obtain the full text for each potentially relevant study in order to assess
eligibility. At each of these stages, a second author will independently screen/assess 10% of studies. Two authors will
independently extract data and assess the quality of studies using a pre-piloted data extraction form. If appropriate, we
will pool estimates of effect for each genotype on each outcome using meta-analyses stratified by ethnicity.
Discussion: Our review and meta-analysis will update and add to the existing research in this field. By not restricting
the scope of the review to a specific drug, genetic variant, or toxicity outcome, we hope to synthesise data for
associations between genetic variants and anti-tuberculosis drug-related toxicity outcomes that have previously not
been summarised in systematic reviews, and consequently, add to the knowledge base of the pharmacogenetics of
anti-tuberculosis drugs.
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Background
Tuberculosis (TB) is one of the most important
challenges in global health at the present time. This
infectious disease ranks alongside human immunodefi-
ciency virus as a leading cause of death worldwide; there
were an estimated 1.4 million TB deaths in 2015 [1].
The World Health Organization (WHO) currently
recommends a combination of four first-line drugs for
individuals with drug-susceptible TB: isoniazid, rifampi-
cin, ethambutol and pyrazinamide [1].
TB patients receiving this regimen may experience
serious adverse drug reactions, such as anti-tuberculosis
drug-induced hepatotoxicity (ATDH), which causes a
strain on health care providers due to high morbidity,
mortality and increased treatment costs [2, 3]. Reported
incidence rates of ATDH among patients treated with
standard multidrug treatment vary widely from 2 to
28%, depending on the regimen given and the character-
istics of patients such as age, race and sex [4]. Variability
in the methodology used for data collection and
reporting, and different definitions of ATDH may also
contribute to the wide range of incidence rates.
The proposed genetic risk factors for ATDH include
polymorphisms of the N-acetyltransferase 2 (NAT2),
cytochrome P450 2E1 (CYP2E1), and glutathione s-
transferase mu 1 (GSTM1) genes, which code for drug-
metabolising enzymes. Several studies have investigated
the association between these genetic polymorphisms
and ATDH [5–24]. These polymorphisms may affect the
activation ability of the enzymes, altering the chemical
modification of anti-tuberculosis drugs and their metab-
olites in the liver, leading to hepatic adverse reactions
[25]. Toxic metabolites may also cause other toxicity
events, such as peripheral neuropathy and maculopapu-
lar eruption, although the majority of evidence on the
pharmacogenetics of anti-tuberculosis drugs focuses on
hepatotoxicity.
Isoniazid is the anti-tuberculosis drug for which the
genetic contribution to ATDH is most studied and best
understood. Specifically, it is thought that NAT2 acetyla-
tor status may be associated with increased risk of
isoniazid-related hepatic adverse reactions, as NAT2 is
one of the main enzymes involved in the metabolism of
isoniazid in the liver. There are three phenotypes of
acetylator status. Individuals who are slow NAT2 acetyla-
tors acetylate isoniazid slowly, resulting in high plasma
drug levels. This may be beneficial for treatment efficacy,
but slow acetylators may also experience an accumula-
tion of toxic metabolites as part of the metabolic activa-
tion of acetylhydrazine to harmless diacetylhydrazine.
Isoniazid suppresses the acetylation of acetylhydrazine,
hence producing more toxic metabolites, which contrib-
utes to the increased risk of isoniazid hepatitis that slow
acetylators experience [26]. Fast acetylators have lower
plasma drug levels, and so, treatment may be not only
less effective but also less toxic, and intermediate
acetylators fall between these two extremes.
Several studies have investigated the association
between NAT2 genetic variants and hepatotoxicity in
patients treated with isoniazid or isoniazid-containing
regimens [5–18], with most studies reporting significant
associations between NAT genetic variants and ATDH.
However, there is no set method for defining acetylator
status by genotyping, as acetylator status is governed by
polymorphisms in a number of alleles on the NAT2
gene, making the genetic definition of acetylator status
difficult to standardise. Cai et al. (2012) [27] defined
individuals without a copy of the wild-type NAT2*4 al-
lele as slow acetylators, and all other individuals as rapid
acetylators, whereas Wang et al. [28] considered individ-
uals with two copies of rapid NAT2 acetylator alleles
(NAT2*4, NAT2*11A, NAT2*12A, NAT2*12B, NAT2*12C,
NAT2*13) to be rapid acetylators, individuals with no cop-
ies to be slow acetylators, and those with one copy to be
intermediate acetylators.
Following NAT2 in the disposition of isoniazid is
CYP2E1. It has been reported that isoniazid inhibits
CYP2E1 activity less in individuals with the CYP2E1
*1A/*1A genotype than in those with other genotypes
[20]. Consequently, individuals with the CYP2E1 *1A/
*1A genotype have higher CYP2E1 activity, resulting in
more hepatotoxins. Some studies have investigated the
association between CYP2E1 genetic variants and
hepatotoxicity in patients treated with isoniazid or
isoniazid-containing regimens, although results from
these studies are often conflicting [13–22].
Finally, GST is an enzyme that plays a crucial role in the
detoxification process, and it has been hypothesised that
individuals with null GSTM1 or GSTT1 genotypes may
detoxify the toxic metabolites from earlier in the meta-
bolic pathway of isoniazid less efficiently [27]. There has
been some investigation into the association between
GSTM1 and GSTT1 genotypes and ATDH [18, 22–24],
and although significant associations are reported by some
studies, the evidence base remains highly uncertain.
Rifampicin and pyrazinamide have also been reported
to be hepatotoxic [29, 30]; however, the mechanisms for
rifampicin-induced hepatotoxicity and pyrazinamide-
induced hepatotoxicity are unknown and unpredictable
[4]. Some speculated genetic variants, such as SLCO1B1,
have been linked to toxicity with rifampicin, although
limited data are available to support this claim [29]. No
hepatotoxicity has been described for ethambutol.
The purpose of this systematic review and meta-
analysis is to evaluate the current evidence on the effect
of genetic variants on anti-tuberculosis drug-related
toxicity in TB patients receiving anti-tuberculosis drugs.
Meta-analyses investigating the pharmacogenetics of
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anti-tuberculosis agents and toxicity outcomes have been
published previously [25, 27, 28, 31–38]. However,
conclusions from these meta-analyses are conflicting.
For example, Cai et al. (2012) [27] and Du et al. [33]
found a significant association between the slow
acetylator NAT2 genotype (i.e., individuals who did not
have the NAT2*4 allele) and increased risk of anti-
tuberculosis drug-induced liver injury (ATDILI);
however, Sun et al. [25] investigated the same genotype
and found no significant association. Furthermore, Cai
et al. (2012) [27] found a significant association between
CYP2E1 c1/c1 genotype and ATDILI for East Asian
populations only, whereas Deng et al. [32], Sheng et al.
[35] and Sun et al. [25] identified a significant associ-
ation regardless of ethnicity. A summary of the findings
of the previously conducted meta-analyses is provided in
Table 1.
Despite the informative nature of the previously con-
ducted meta-analyses, there are several methodological
limitations to these reviews.
 Cai et al. (2012) [27] only included studies that
provided genotype distribution information in both
cases and controls, or the odds ratio (OR) with its
95% confidence interval (CI) and p value. It is highly
likely that some papers would not report either of
these details, and therefore, key evidence may have
been omitted from this systematic review. Li et al.
[34] and Shi et al. [36] both also excluded papers
without genotype data for both cases and controls.
Deng et al. [32], Du et al. [33], Sheng et al. [35],
Tang et al. [37], Wang et al. [28] and Wang et al.
[38] also excluded papers if reported data were
insufficient to calculate ORs.
 Cai et al. (2012) [27] excluded three studies that
were “non-RCTs”. No definition of “non-RCT”
was provided, although we assume the authors
are referring to studies that are not randomised
controlled trials (RCTs). Pharmacogenetic studies
are likely to be non-randomised studies, such as
case–control or cohort designs, so this is not a
valid reason for excluding studies, and important
evidence may have been omitted from the
meta-analysis.
 Cai et al. (2015) [31], Deng et al. [32], Li et al. [34],
Sheng et al. [35], Shi et al. [36], Sun et al. [25], Tang
et al. [37] and Wang et al. [28] all included only
case–control studies. While it does not seem as
though any studies were excluded on this basis for
most of the reviews, Sun et al. [25] did not provide a
literature search map, and so, it is unclear whether
any studies were excluded on this basis.
Furthermore, it is not clear from the literature
search map provided in Cai et al. (2015) [31]
whether any non-case–control studies were
excluded. Genetic association data may come from
non-case–control studies, such as RCTs.
 Cai et al. (2012) [27], Cai et al. (2015) [31], Du et al.
[33] and Li et al. [34] did not assess study quality,
which is a key component of any systematic review.
 Sun et al. [25] did assess study quality using Little’s
checklist [39]; however, the review authors deemed
two studies to be of poor quality but did not
investigate the impact of including these poor
quality studies in the meta-analyses.
In order to overcome these limitations, our systematic
review and meta-analysis will not exclude papers if
sufficient data are not reported; instead, we will contact
study authors to obtain the required information. Our
review will include both non-RCTs and RCTs if relevant
data are measured. We will also assess studies with
respect to their quality and strength of evidence and
investigate the impact of including poor-quality studies
by conducting sensitivity analyses.
In addition, the scope of our review will be wider than
the previously conducted meta-analyses. Cai et al. (2012)
[27] and Sun et al. [25] excluded studies if they did not
report hepatotoxicity. Our meta-analysis will consider all
effects of genetic polymorphisms on all toxicity
outcomes. Furthermore, all previously conducted meta-
analyses restricted inclusion to those studies that
considered specific genes; our review will include all
pharmacogenetic studies in this field. In addition, as the
most recent of these meta-analyses included papers up
to November 2013, our review may include additional
evidence from studies published in the past 3 years,
which would not have been included in any of the
previously published meta-analyses.
Our review and meta-analysis will update and add to
the existing research which has previously been
conducted in this field.
Methods
This protocol has been prepared in accordance with the
Preferred Reporting Items for Systematic Review and
Meta-analysis Protocols (PRISMA-P) statement [40], as
provided in Additional file 1.
Selection criteria
Types of studies: We expect that most studies identified
will be retrospective or prospective cohort studies;
however, we will also include case–control studies and
RCTs. Case–control studies may have been conducted to
compare patients who experienced toxicity events with
those who did not. RCTs may have been conducted to
investigate the effectiveness of genotyping TB patients
before prescribing anti-tuberculosis agents. In this case,
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we would include data from patients in the genotyped
arm of the trial. We may also identify RCTs in which
none of the patients were originally genotyped, but a
subsequent post hoc genetic analysis was conducted in a
subset of patients or in the whole trial population, and
we will also include these studies.
Types of participants: We will include studies that
recruited TB patients who were either already established
on anti-tuberculosis treatment or commencing treatment
and who were genotyped to investigate the effect of gen-
etic variants on anti-tuberculosis drug-related toxicity.
Types of outcomes: We will include studies that
measured any toxicity outcomes.
Inclusion/exclusion criteria
Studies will have to satisfy the following inclusion
criteria to be included in our review.
 The majority of patients should have been TB
patients receiving anti-tuberculosis treatment (at
least one of isoniazid, rifampicin, pyrazinamide or
ethambutol).
 Patients should have been genotyped.
 Association between at least one genetic variant and at
least one toxicity outcome should have been assessed.
Studies will be excluded if either of the following
exclusion criteria is met.
 The only outcomes were pharmacokinetic
outcomes.
 A case study design was used.
Outcomes
The primary outcome of our review will be hepatotox-
icity by any definition. Secondary outcome will be all
other toxicity outcomes.
Identification of studies
A search specialist will design the search strategy and will
search for relevant studies in MEDLINE, PUBMED,
EMBASE, BIOSIS and Web of Science. The following Med-
ical Subject Headings (MeSH) words will be used as part of
our search strategy: antitubercular agents, antitubercular
drugs, isoniazid, rifampicin, pyrazinamide, ethambutol, gen-
etic polymorphism, genetic susceptibility, pharmacogenet-
ics, pharmacogenomics, genetic association study, genetic
association analysis, tuberculosis. Details of the planned
search strategy are provided in Additional file 2.
We will hand search reference lists from relevant
studies and contact experts in the field, in order to iden-
tify further eligible studies. We will include studies pub-
lished in English only. We will not restrict by year of
publication or publication status.
Once we have a complete list of studies identified by
the search, literature search results will be imported to
Covidence [41], an Internet-based software programme
that facilitates collaboration among reviewers during the
study selection process. We will remove duplicates, and
one author (MR) will independently scan the abstracts
of these studies to remove any obviously irrelevant
studies. A second author (AJ or JK) will independently
screen a sample of 10% of studies.
We will obtain the full text for each potentially
relevant study. One reviewer (MR) will independently
assess eligibility for inclusion in the review based on the
inclusion and exclusion criteria. A second author (AJ or
JK) will independently assess a sample of 10% of studies
for inclusion. We will seek additional information from
study authors where necessary to resolve questions
about eligibility. Any disagreements between the two
reviewers will be resolved through discussion and by
consulting a third author if necessary.
For conference abstracts that satisfy our inclusion cri-
teria, and for conference abstracts for which eligibility is
unclear, we will attempt to locate the full journal article
by searching for the studies online or by contacting the
conference abstract authors, in order to guide our
eligibility judgement. If we are unable to locate the full
paper, or if the authors confirm that the work has not
been published in full, we will exclude these studies. If
we identify the full paper for an eligible study, we will
add this study to our included studies.
Data collection
Two authors will independently extract data in accord-
ance with the methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions [42]
and as recommended in The HuGENet HuGE Review
Handbook [43]. We will design a data extraction form
and pilot this using a random sample of the studies to
be reviewed. We will collect data on study design,
participant characteristics, treatment regimen and
outcomes. The form will also enable us to assess study
quality, as described below. We will contact authors of
the studies if we require additional information in order
to assess study quality or the appropriateness of pooling
data from different studies, and if outcome data required
to calculate effect sizes are missing. Any disagreements
between the two reviewers will be resolved through
discussion and by consulting a third author if necessary.
Assessment of study quality
Two authors will use the criteria in Table 2, as devel-
oped in a previous meta-analysis of pharmacogenetics
studies [44], to assess the quality of each included study,
at study level, in relation to specific genetic association
study issues. Any disagreements between the two
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reviewers will be resolved through discussion and by
consulting a third author if necessary.
Data synthesis
Where possible, we will pool the estimates of effect for
each genotype on each outcome. We will consider the
differences in definition of hepatotoxicity or other
toxicity outcomes and perform stratified analyses if it is
not clinically meaningful to combine results for different
definitions of outcomes in meta-analysis.
We will decide on which genotype groups to compare
based on the primary papers. If primary papers vary in
terms of which genotype groups they compare, we will use
methods proposed in the literature to combine these [45].
Table 2 Criteria for quality assessment of genetic association studies
Issue Assessment criteria
1. Choosing the genes/single-nucleotide
polymorphisms (SNPs) to genotype
Was a literature review undertaken and the findings summarised?
Are reasons given for choosing the genes and SNPs genotyped?
If reasons include previous association studies, are key details from
these provided?
If reasons include functional studies are supporting data provided?
Is method to adjust for multiple testing described?
Are precise p values provided for all associations?
2. Sample size What is the sample size?
Are details given of how the sample size was calculated?
Are details given of the a priori power to detect effect sizes of varying
degrees?
3. Study design What is the study design?
If study is case–control, are the two groups clearly defined?
If study is case-control, were they genotyped in mixed batches?
4. Reliability of genotypes Is the genotyping procedure described?
Are the primers described?
Were quality control methods used and described?
Were findings from quality control methods, if used, described?
Are any genotype frequencies previously reported quoted?
Were genotyping personnel blinded to outcome status?
If human inference required, was this independently undertaken by at
least two people?
5. Missing genotype data Is extent of missing data summarised?
Where extent is summarised are reasons for missing data given?
Are checks for missingness at random reported?
Are missing genotype data imputed?
Does paper quote number of patients contributing to each analysis?
If paper does quote number of patients contributing to analyses, does
this agree to sample size?
6. Population stratification Are tests undertaken for cryptic population stratification?
If so, are results quoted?
Is cryptic population stratification adjusted for in the analyses?
7. Hardy–Weinberg equilibrium (HWE) What test is undertaken to check for HWE?
Where test undertaken, is p value threshold applied to determine deviation
from HWE quoted?
Where test undertaken, are SNPs deviating from HWE highlighted?
Where test undertaken, and some SNPs found to deviate, are steps taken
to explore deviation from HWE reported?
Where test undertaken, and some SNPs found
to deviate, are deviating SNPs excluded from further analysis?
8. Mode of inheritance Is a specific mode of inheritance assumed? If so which?
Is justification provided for assumptions made regarding mode of inheritance
(if no mode or a specific mode is assumed)?
If no mode of inheritance is assumed does the paper explain limitations of this?
If several analyses undertaken under different assumptions, are they adjusted
for multiple testing?
9. Choice and definition of outcomes Does the paper clearly define all outcomes investigated?
Is justification provided for the choice of outcomes?
Are results shown for all outcomes mentioned?
10. Adherence to treatment Is adherence to treatment measured?
If adherence is measured, are adjustments for non-adherence made in the analyses?
HWE Hardy–Weinberg equilibrium, SNP single-nucleotide polymorphism
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As we do not know the genetic model underlying the
effects of the various genetic polymorphisms, we will
implement a “genetic model-free” [46] approach when
pooling effect estimates. This approach assumes a
common genetic model across all studies included in a
meta-analysis, which is estimated from the data. If the
data suggest that this assumption is violated, we will use
a bivariate meta-analysis model to conduct joint pairwise
comparisons. This model accounts for the fact that the
effect measures for homozygous-mutant versus homozy-
gous wild-type genotypes and for heterozygous versus
homozygous wild-type genotypes will be correlated.
We will perform meta-analyses using R, generating
ORs and 95% CIs for dichotomous data, and mean
differences and standard errors for continuous data. For-
est plots will be produced. We will assess heterogeneity
by visually examining the forest plots and by considering
the I2 statistic [47]. If heterogeneity is minimal, we will
perform meta-analysis using fixed-effects models. If
considerable heterogeneity is observed, we will attempt
to explain this heterogeneity using subgroup analyses.
However, if some unexplained heterogeneity remains, we
will use random-effects models for meta-analysis. Finally,
if heterogeneity is substantial and cannot be explained by
subgroup analyses, we may decide that it is not appropri-
ate to perform any meta-analysis of the data. If included
studies are too heterogeneous to combine in a meta-
analysis, we will display the results of included studies in a
forest plot but suppress the pooled estimate, and we will
summarise the results of the included studies descriptively
in the text and tables of the review.
Investigation of heterogeneity and subgroup analysis
We will perform stratified analyses by ethnic groups, and
if effect estimates are found to be similar across different
ethnic groups, then we will pool these results. We may
use meta-regression to investigate the effect of continuous
variables on treatment effect or, if it is appropriate, to in-
vestigate the effects of multiple factors in the same ana-
lysis. We will not carry out meta-regression if fewer than
10 studies are included in the meta-analysis.
If heterogeneity exists, we will investigate this hetero-
geneity by performing subgroup analyses according to
ethnic groups, study design, outcome definitions,
treatment regimens, and date of study publication, as
early studies often overestimate effects.
Selective reporting
We will attempt to identify cases of selective reporting
within the included studies by constructing an outcome
matrix [48], with the review outcomes and outcomes
reported by included studies listed. We will scrutinise
studies with missing outcome data and will contact the
authors of the study if a study does not report results for
the outcomes of interest. We will not exclude studies on
the basis of missing outcome data [49]. We will perform
sensitivity analyses to assess the robustness of the con-
clusions of meta-analyses to outcome reporting bias
[50–52]. We will also scrutinise studies in order to iden-
tify possible selective reporting with regard to reporting
results for all pre-specified genetic variants.
Publication bias
We will produce funnel plots if enough studies are available
(>10 studies), in order to assess the risk of publication bias.
Sensitivity analyses
We will perform sensitivity analyses excluding poor-
quality studies, in order to assess the impact of these
studies on pooled effect estimates.
Confidence in cumulative evidence
The strength of the body of evidence will be assessed ac-
cording to the Venice interim criteria [53].
Discussion
We do not anticipate that there will be any practical or
operational issues in the implementation of this protocol.
There is a key issue that we will consider when performing
our systematic review and meta-analysis, and interpreting
the results––namely, the scope of the available data with
regard to geographical location. There is a great deal of
genetic variability across the African continent, where TB
is endemic, and there is very little mapping of pharmaco-
genomic polymorphisms in African populations. Although
we will assess the quality of included studies with regard
to possible cryptic population stratification, and we will
perform subgroup analyses by ethnic group to investigate
how estimates of effect for genetic variants on toxicity
outcomes vary according to population, it may be the case
that results are still not representative of the global popu-
lation most affected by TB.
Additional files
Additional file 1: PRISMA-P 2015 checklist. Containing the populated
PRISMA-P checklist table, demonstrating how this protocol has been
prepared in accordance with the PRISMA-P statement. (DOCX 33 kb)
Additional file 2: Search strategy. Outlining the search terms and
search strategy that we will use to identify studies to include in our
systematic review and meta-analysis. (DOCX 20 kb)
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